Team provides new insights into HIV prevention for cisgender women

Globally speaking, most HIV infections in young women occur in poorer countries, where up to 25% of women may be infected with the HIV virus. For heterosexual women, prevention through the use of Pre-Exposure Prophylaxis (PrEP) and its active ingredients, emtricitabine/tenofovir, represents one of the few options available to protect themselves from HIV infection. Additionally, it is a very inexpensive drug, available in most resource-constrained countries.